Loading
The first trial in which a new pill beat sorafenib on survival in liver cancer, with a Chinese deuterated redesign of sorafenib itself.
668 patients, open label. Median overall survival 12.1 versus 10.3 months (hazard ratio 0.83) with fewer grade 3 or higher adverse events; published in the Journal of Clinical Oncology 2021. NMPA approval June 2021. A small gain, but the first head-to-head overall survival win against sorafenib and an example of incremental medicinal chemistry rewarded in China's market.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Sorafenib, Hepatocellular carcinoma and the tag china.
Shares Shukui Qin, Hepatocellular carcinoma, Small-molecule kinase inhibitors and the tag china.
Shares Hepatocellular carcinoma and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Hepatocellular carcinoma and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.